{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"600"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"}],"units":"Participants"}],"description":"RP2D was defined as the highest dose with acceptable toxicity as determined from Phase I of the study.","groups":[{"description":"Participants received single dose of 20 or 40 or 150 mg alectinib capsules orally to make a dose of 240, 300, 460, 600, 760, or 900 mg on Cycle 1 Day -3 and then received 600 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","id":"OG000","title":"Alectinib: Phase I"}],"paramType":"NUMBER","populationDescription":"Phase I safety population","reportingStatus":"POSTED","timeFrame":"Throughout Cycle 1 of Phase I (21 days)","title":"Recommended Phase II Dose (RP2D): Phase I","type":"PRIMARY","unitOfMeasure":"mg"}